logo
  Join        Login             Stock Quote

Myriad Genetics (MYGN) PT Lifted By Oppenheimer After Q3, 'Perform' Maintained

 May 02, 2012 12:54 PM


(By Balaseshan) Oppenheimer & Co. analyst David Ferreiro raised his price target on shares of Myriad Genetics Inc. (NASDAQ:MYGN) to $29 from $22, while maintaining "Perform" rating given the uncertainty around the impact of CPT coding reform.

After the company's third quarter results, the brokerage increased its 2012 EPS estimate to $1.29 from $1.26 and its 2013 estimate to $1.43 from $1.38. The firm cut its 2012 revenue estimate to $493.5 million from $469.4 million and its 2013 estimate to $553.3 million from $486.0 million.

The company's Q3 revenue of $129.8 million was above Ferreiro's estimate of $116 million and Street estimate of $120 million. This translated to EPS of $0.34 (up 11% year-over-year growth) above his estimate of $0.31 and the Street's forecast of $0.32. On the quarter, MYGN repurchased 502,000 shares ($161 million remaining on $200 million authorization).

[Related -Health Net, Inc. (HNT): Potential to Be Huge Winners Says Bank of America]

Third quarter revenue growth of 27% (21% organic) was driven by BRACAnalysis growth in new indications and the emergence of Colaris. Progress with MYGN's European expansion plan remains ahead of schedule with European labs open and accepting samples.

As expected, MYGN has stepped up the commercialization efforts for Prolaris, securing the publication of a clinical study (Pro-003) and plans to increase the sales force to 20. In total MYGN will have tested Prolaris in 3,500 patients across 9 studies. Ferreiro is encouraged by the company's progress, both commercially and on the developmental front.

[Related -HomeAway, Inc. (AWAY) Q2 Earnings Preview: Top and Bottom Line Bullish Surprise?]

MYGN has nine clinical trials underway, with PRO-009 studying 450 radical prostatectomy patients and expected publication in 2013. Upon completion, Prolaris will have been tested in about 3,500 patients. With a doubling of the sales force and payor talks underway, the analyst expects Prolaris to start making a material impact by 2014.

MYGN has raised guidance to revenue of $492 million to $496 million versus previous guidance of $445 million to $465 million. This translates to earnings of $1.29 to $1.31 per share range versus the original estimate of $1.20 to $1.25 per share.

Myriad Genetics, which is a molecular diagnostic company, is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of the molecular diagnostic testing and analysis for its tests in its own reference laboratory.

MYGN is trading up 2.04% at $26.50 on Wednesday.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageChipotle Mexican Grill, Inc. (CMG) Q2 Earnings Preview: Will Higher Traffic Offset Higher Costs the Key

Chipotle Mexican Grill, Inc. (NYSE:CMG) will host a conference call to discuss second quarter 2014 read on...

article imageNetflix, Inc. (NFLX) Q2 Earnings Preview: The Ruby Month for a Reason

Netflix, Inc. (NASDAQ:NFLX) will post its second-quarter 2014 financial results and business outlook on its read on...

article imageLadenburg Thalmann Financial Services (NYSEMKT:LTS): Heavy, Durable Insider Buying

Ahh, but any worries over price levels didn’t stop multiple insiders at Ladenburg Thalmann Financial read on...

article imageInternational Business Machines Corp. (IBM) Q2 Earnings Preview: Small Beat and Pop

International Business Machines Corp. (NYSE:IBM) will host a conference call Wednesday, Jul. 16, 2014 at read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.